Malta Health Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Funding
• Alerts
• Clinical Trials
• Forums

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Conditions:   Follicular Lymphoma;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Waldenstrom Macroglobulinemia;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma;   Indolent Lymphoma;   Refractory B-Cell Lymphoma;   MALT Lymphoma Intervention:   Drug: PSB202 Sponsor:   Qilu Puget Sound Biotherapeutics (dba Sound Biologics) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 12, 2021 Category: Research Source Type: clinical trials